Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution

References

• Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplant 2012;47:906–923
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–854
   PubMed Web of Science ®Google Scholar
• Storb R. Allogeneic hematopoietic stem cell transplantation – yesterday, today, and tomorrow. Exp Hematol 2003;31:1–10
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550–1561
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006;203:2021–2031
   PubMed Web of Science ®Google Scholar
• Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994;83:2360–2367
   PubMed Web of Science ®Google Scholar
• Casper J, Wolff D, Knauf W, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010;28:3344–3351
   PubMed Web of Science ®Google Scholar
• Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001;29:362–370
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–3400
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756–762
   PubMed Web of Science ®Google Scholar
• Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011;118:6438–6445
   PubMed Web of Science ®Google Scholar
• Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 2003;76:297–305
   PubMed Web of Science ®Google Scholar
• Mapara MY, Pelot M, Zhao G, et al. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 2001;7:646–655
   PubMed Web of Science ®Google Scholar
• Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998;92:3960–3967
   PubMed Web of Science ®Google Scholar
• Ploemacher RE, Johnson KW, Rombouts EJ, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004;10:236–245
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Aghdami N, Hassan Z, et al. GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant 2008;42:807–818
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Al-Hashmi S, Hassan Z, et al. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin Dev Immunol 2010;2010:142943
   PubMedGoogle Scholar
• Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 2012;59:1079–1087
   Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001;98:3456–3464
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Ploemacher RE, Boudewijn A, et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000;60:5470–5478
   PubMed Web of Science ®Google Scholar
• Bouazzaoui A, Spacenko E, Mueller G, et al. Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. Exp Hematol 2011;39:238–249 e1
   PubMed Web of Science ®Google Scholar
• Bouazzaoui A, Spacenko E, Mueller G, et al. Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease. Genes Immun 2009;10:687–701
   PubMed Web of Science ®Google Scholar
• Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988;167:570–581
   PubMed Web of Science ®Google Scholar
• Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29:259–277
   PubMed Web of Science ®Google Scholar
• Brown GR, Lee EL, Thiele DL. TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms. J Immunol 2003;170:5082–5088
   PubMed Web of Science ®Google Scholar
• Gerbitz A, Nickoloff BJ, Olkiewicz K, et al. A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation 2004;78:494–502
   PubMed Web of Science ®Google Scholar
• Hildebrandt GC, Olkiewicz KM, Corrion LA, et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004;104:586–593
   PubMed Web of Science ®Google Scholar
• Cao H, Wolff RG, Meltzer MS, Crawford RM. Differential regulation of class II MHC determinants on macrophages by IFN-gamma and IL-4. J Immunol 1989;143:3524–3531
   PubMed Web of Science ®Google Scholar
• Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993;259:1739–1742
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35
   PubMed Web of Science ®Google Scholar
• Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993;259:1742–1745
   PubMed Web of Science ®Google Scholar
• Duffield JS, Ware CF, Ryffel B, Savill J. Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages. Am J Pathol 2001;159:1397–1404
   PubMed Web of Science ®Google Scholar
• Sender V, Hofmeister-Mielke N, Sievert K, et al. Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. Immunopharmacol Immunotoxicol 2009;31:595–600
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Mohren M, Jentsch-Ullrich K, et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004;34:477–483
   PubMed Web of Science ®Google Scholar
• Reichle A, Holler E, Berand A, Andreesen R. Treosulfan-based tandem high-dose chemo-immuno therapy with autologous stem cell transplantation for relapsed and refractory aggressive B-cell lymphomas. Blood 2005;106:5488
   Web of Science ®Google Scholar
• Shono Y, Ueha S, Wang Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 2010;115:5401–5411
   PubMed Web of Science ®Google Scholar
• Fedoriw Y, Samulski TD, Deal AM, et al. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biol Blood Marrow Transplant 2012;18:968–973
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Terakura S, Ito M, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009;114:3113–3116
   PubMed Web of Science ®Google Scholar
• Kreutz M, Karrer S, Hoffmann P, et al. Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. J Invest Dermatol 2012;132:179–187
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–415
   PubMed Web of Science ®Google Scholar